FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT	OF	CHANGES	IN BE	NEFICIAL	OWNERSHIP)

OMB APPROVAL									
OMB Number: 3235-0									
Estimated average burden									
hours per response:	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* <u>Vuori Kristiina MD</u>				2. Issuer Name and Ticker or Trading Symbol Bionano Genomics, Inc. [BNGO]								Relationship of eck all applic X Directo	able)	g Perso	10% Ov	vner		
(Last)	,	irst) NOMICS, INC.	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/30/2020								Officer below)	(give title		Other (s below)	pecify
9540 TOWNE CENTRE DRIVE, SUITE 100					If Amendment, Date of Original Filed (Month/Day/Year)								6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SAN DII	EGO C	A	92121		07/	07/02/2020						X Form filed by One Reporting Person Form filed by More than One Reporting Person			- 1			
(City)	(S	itate)	(Zip)															
		Та	ble I - Non	-Deriv	ativ	e Se	curitie	s A	cquired,	Dis	posed of	, or Ber	eficial	y Owned				
			2. Transa Date (Month/I	action 2A. Deemed Execution Date if any (Month/Day/Yea		e, Transaction Disposed Of (E Code (Instr. 5)		es Acquired (A) or Of (D) (Instr. 3, 4 and		5. Amour Securitie Beneficia Owned F Reported	For		m: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
							Code	٧	Amount	(A) or (D)		Transacti (Instr. 3 a	ion(s)			11301. 4/		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 3. Transaction Date Execution Date (Month/Day/Year) if any (Month/Day/Year)		te, Tr	4. Transaction Code (Instr. 8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amo of Securities Underlying Derivative Secur (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)			
				Co	ode ,	v	(A)	(D)	Date Exercisab		xpiration ate	Title	Amount or Number of Shares					
Stock Option (Right to Buy)	\$0.51	06/30/2020			A		44,470		(1)	0	6/30/2030 ⁽²⁾	Common Stock	44,470	\$0.00	44,47	0	D	

Explanation of Responses:

- 1. The shares vest in equal monthly installments over a one year period such that the option is fully vested on June 30, 2021, subject to full vesting acceleration upon a change in control (as defined in Bionano Genomic's equity incentive plan).
- 2. The acquisition of the reported option was reported in a Form 4 filed on July 2, 2020, which mistakenly reported the expiration date as 06/30/2029.

Remarks:

/s/ R. Erik Holmlin, Attorneyin-Fact 07/18/2022

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.